Education
About Us
Working with TipRanks
Follow Us
ConvaTec (GB:CTEC)
LSE:CTEC
Earnings Data
Report Date
Aug 04, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
―Last Year’s EPS
0.06Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call conveyed a generally positive financial and operational performance: strong organic growth excluding the InnovaMatrix disruption, margin expansion, double-digit EPS growth, robust cash generation, increased growth CapEx and an active return-of-capital program. Key strategic strengths include a broad-based pipeline, improving product launches (notably Infusion Care), and clear 2026 and 2027 targets. However, material near-term challenges temper the outlook: a severe CMS-driven price cut and $72 million impairment for InnovaMatrix, an FDA warning letter on complaints/CAPA processes, inflationary pressure, and execution/capacity risks that management is addressing. Overall, the positives (growth, margins, cash, pipeline, capital allocation) substantially outweigh the negatives, though the operational and regulatory issues warrant active mitigation.Company Guidance
Consistent Organic Revenue Growth
Five consecutive years of organic revenue growth within target range; 2025 organic revenue growth of 6.4% excluding InnovaMatrix, and company note of five years >5% and three years >6% (ex-InnovaMatrix). 2026 guidance: 5%–7% organic growth (ex-InnovaMatrix) and long-term target of 6%–8% p.a. from 2027.
Operating Margin Expansion
Operating margin expanded 110 basis points in 2025 to 22.3%; cumulative margin expansion of 460 basis points since 2021. Company expects at least 23% operating margin in 2026 and mid-20s in the medium term.
Double-Digit EPS Growth and Profitability
Earnings per share grew 16% in 2025 (net profit up 15%); operating profit up 12% and EBITDA increased 12%. Management expects another year of double-digit EPS growth in 2026.
Strong Cash Generation and Capital Allocation
Free cash to equity of $362 million and conversion of 101% under new definition; free cash flow conversion target around 100% for 2026. Returned capital via $300 million share buyback in H2 2025 and dividend growth of 13%.
Increased Investment to Support Growth
Growth CapEx more than doubled to $121 million in 2025; operational CapEx steady at ~2.5% of sales. Management plans to continue increasing growth CapEx to expand capacity and support pipeline.
Infusion Care Outperformance
Infusion Care delivered double-digit organic growth of 12.5% in 2025 (standout category). Nondiabetes therapies grew share to 15% of Infusion Care revenue (from ~10% in 2024). Company targets high single-digit Infusion Care growth in 2026 and expects further acceleration with additional capacity.
Solid Performance in Continence and Ostomy Care
Continence Care grew 6.6% organically in 2025 with hydrophilic products representing >60% of category revenue and ConvaTec product share at 59%. Ostomy Care grew 4.5% organically; Esteem Body exceeded expectations and the company secured new GPO wins in the U.S.
Broad-Based New Product Pipeline
Eight product launches underway in-market and eight more planned across 2026–2027; management describes the richest product pipeline in company history and expects launches to drive acceleration to 6%–8% organic growth from 2027.
GB:CTEC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GB:CTEC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 24, 2026 | 227.00p | 250.60p | +10.40% |
Jul 29, 2025 | 237.43p | 243.00p | +2.35% |
Feb 26, 2025 | 242.11p | 253.87p | +4.86% |
Jul 30, 2024 | 245.33p | 231.11p | -5.80% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does ConvaTec (GB:CTEC) report earnings?
ConvaTec (GB:CTEC) is schdueled to report earning on Aug 04, 2026, TBA (Confirmed).
What is ConvaTec (GB:CTEC) earnings time?
ConvaTec (GB:CTEC) earnings time is at Aug 04, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of ConvaTec stock?
The P/E ratio of ConvaTec is N/A.
What is GB:CTEC EPS forecast?
Currently, no data Available